Compounds > iodixanol
Page last updated: 2024-10-29

iodixanol and Acute Coronary Syndrome

iodixanol has been researched along with Acute Coronary Syndrome in 5 studies

iodixanol: dimeric contrast media; structure given in first source
iodixanol : A dimeric, non-ionic, water-soluble, radiographic contrast agent, used particularly in coronary angiography.

Acute Coronary Syndrome: An episode of MYOCARDIAL ISCHEMIA that generally lasts longer than a transient anginal episode that ultimately may lead to MYOCARDIAL INFARCTION.

Research Excerpts

ExcerptRelevanceReference
"Iodixanol 320 was found to have the best image quality/side-effect ratio and enabled the study of long arterial segments."2.45[The non-occlusive modality of optical coherence tomography image acquisition: a new concept for wide clinical application]. ( Albertucci, M; Fernandez, B; Prati, F; Ramazzotti, V, 2009)

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (40.00)29.6817
2010's3 (60.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Kobalava, ZD1
Villevalde, SV1
Gaskina, AA1
Mayskov, VV1
Moiseev, VS1
Valero, E1
Rodríguez, JC1
Moyano, P1
Miñana, G1
Sanchis, J1
Núñez, J1
Ulimoen, GR1
Gjønnaess, E1
Atar, D1
Dahl, T1
Stranden, E1
Sandbaek, G1
Prati, F1
Ramazzotti, V1
Fernandez, B1
Albertucci, M1
Tardif, JC1
L'allier, PL1
Ibrahim, R1
Grégoire, JC1
Nozza, A1
Cossette, M1
Kouz, S1
Lavoie, MA1
Paquin, J1
Brotz, TM1
Taub, R1
Pressacco, J1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Clinical Study Protocol No. VIA-2291-01, A Phase 2 Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-ranging Study of the Effect of VIA-2291 on Vascular Inflammation in Patients After an Acute Coronary Syndrome Event[NCT00358826]Phase 2191 participants (Actual)Interventional2006-07-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change From Baseline in High Sensitivity C-reactive Protein (hsCRP) - Core Study

(NCT00358826)
Timeframe: Baseline and 12 weeks

Interventionmg/L (Median)
VIA-2291 25 mg-0.2
VIA-2291 50 mg-0.1
VIA-2291 100 mg-0.3
Placebo-0.2

Change From Baseline in High Sensitivity C-reactive Protein (hsCRP) - MDCT Substudy

(NCT00358826)
Timeframe: Baseline and 24 weeks

Interventionmg/L (Median)
VIA-2291 25 mg MDCT Substudy-0.4
VIA-2291 50 mg MDCT Substudy-0.2
VIA-2291 100 mg MDCT Substudy-0.4
Placebo MDCT Substudy0.0

Change From Baseline in Leukotriene E4 (LTE4)

Urinary LTE4 is expressed in pg per mg Creatinine (pg/mg Cr) to normalize for renal excretion rate (NCT00358826)
Timeframe: Baseline and 12 weeks

Interventionpg/mg Cr (Least Squares Mean)
VIA-2291 25 mg-26.8
VIA-2291 50 mg-38.6
VIA-2291 100 mg-56.5
Placebo8.4

Change From Baseline in Mean Plaque Density

Plaque density is expressed in Hounsfield Units (HU) (NCT00358826)
Timeframe: Baseline and 24 weeks

InterventionHU (Least Squares Mean)
VIA-2291 25 mg19.11
VIA-2291 50 mg7.39
VIA-2291 100 mg12.22
Placebo12.42

Change From Baseline in Noncalcified Plaque Volume

(NCT00358826)
Timeframe: Baseline and 24 weeks

Interventionmm^3 (Least Squares Mean)
VIA-2291 25 mg MDCT Substudy-1.55
VIA-2291 50 mg MDCT Substudy-5.6
VIA-2291 100 mg MDCT Substudy0.15
Placebo MDCT Substudy2.83

Change From Baseline in Percent Stenosis

(NCT00358826)
Timeframe: Baseline and 24 weeks

InterventionPercentage (Least Squares Mean)
VIA-2291 25 mg-0.11
VIA-2291 50 mg11.45
VIA-2291 100 mg2.36
Placebo1.19

Change From Baseline on ex Vivo Leukotriene B4 Synthesis in Whole Blood

(NCT00358826)
Timeframe: Baseline and 12 weeks

Interventionpg/mL (Least Squares Mean)
VIA-2291 25 mg-88126
VIA-2291 50 mg-95703
VIA-2291 100 mg-122668
Placebo-20843

Reviews

1 review available for iodixanol and Acute Coronary Syndrome

ArticleYear
[The non-occlusive modality of optical coherence tomography image acquisition: a new concept for wide clinical application].
    Giornale italiano di cardiologia (2006), 2009, Volume: 10, Issue:10

    Topics: Acute Coronary Syndrome; Angina Pectoris; Angioplasty, Balloon, Coronary; Animals; Atherosclerosis;

2009

Trials

2 trials available for iodixanol and Acute Coronary Syndrome

ArticleYear
Noninvasive coronary angiography with 64-channel multidetector computed tomography in patients with acute coronary syndrome.
    Acta radiologica (Stockholm, Sweden : 1987), 2008, Volume: 49, Issue:10

    Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Angina, Unstable; Contrast Media; Coronary

2008
Treatment with 5-lipoxygenase inhibitor VIA-2291 (Atreleuton) in patients with recent acute coronary syndrome.
    Circulation. Cardiovascular imaging, 2010, Volume: 3, Issue:3

    Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Analysis of Variance; Arachidonate 5-Lipoxy

2010

Other Studies

2 other studies available for iodixanol and Acute Coronary Syndrome

ArticleYear
[Contrast-induced acute kidney injury after primary percutaneous coronary interventions: Prevalence, predictive factors, and outcomes].
    Terapevticheskii arkhiv, 2015, Volume: 87, Issue:6

    Topics: Acute Coronary Syndrome; Acute Kidney Injury; Adult; Aged; Aged, 80 and over; Contrast Media; Electr

2015
Role of Neutrophil Gelatinase-associated Lipocalin in the Detection of Contrast-induced Nephropathy in Patients Undergoing a Coronary Angiography.
    Revista espanola de cardiologia (English ed.), 2016, Volume: 69, Issue:5

    Topics: Acute Coronary Syndrome; Acute Kidney Injury; Aged; Contrast Media; Coronary Angiography; Creatinine

2016